Durvalumab/Gefitinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Durvalumab/Gefitinib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: CONDITIONAL GO
Decision memo
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
The central underwriting question is whether Durvalumab/Gefitinib can convert its Small molecule drug, Monoclonal antibody profile and EGFR x PDL1 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Durvalumab/Gefitinib (query alias: Durvalumab/Gefitinib) |
|---|---|
| Modality / target | Small molecule drug, Monoclonal antibody; EGFR x PDL1; EGFR antagonists, PDL1 inhibitors |
| Highest global status | Phase 2 |
| Originator | MedImmune LLC |
| Active developers | MedImmune LLC |
The MCP disease footprint includes Non-Small Cell Lung Cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| ChiCTR2600131658 | Phase 3 | Completed | 400 | Primary endpoint not disclosed in English source |
| CTR20263306 | Phase 3 | Not yet recruiting | 140 | Primary endpoint not disclosed in English source |
| JPRN-jRCT2031260435 | Phase 2 | Recruiting | 29 | Primary endpoint not disclosed in English source |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 In Completely Resected Non-Small Cell Lung Cancer
Phase 3; n=1415; evaluation: Not stated in English source. Reported fields: Compare Disease Free Survival (DFS) for Patients With NSCLC That is PD-L1 Expression TC ≥ 25% and Patients Without EGFR Exon 21 L858R Mutation or Exon 19 Deletions or ALK Gene Rearrangements(Median) = 69.9 DFS time in months. (95%CI, 57.6 - NA); Compare Disease Free Survival (DFS) for Patients With NSCLC That is PD-L1 Expression TC ≥ 25% and Patients Without EGFR Exon 21 L858R Mutation or Exon 19 Deletions or ALK Gene Rearrangements(Median) = 60.2 DFS time in months. (95%CI, 47.7 - NA)
Association of TP53/KEAP1 Co-Mutation With Clinical Outcomes in Stage II-III NSCLC Treated With Chemoradiotherapy and Durvalumab
Not Applicable; n=263; evaluation: Positive. Reported fields: Median BMFS = not reached Month ; Median BMFS = 24.2 Month
Staggered Schedule of Chemoimmunotherapy (Durvalumab, Carboplatin and Pemetrexed) for Metastatic Non-Squamous, NSCLC
Phase 2; n=43; evaluation: Positive. Reported fields: RR = 57.0 % ; RR = 36.0 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Durvalumab/Gefitinib addresses Non-Small Cell Lung Cancer. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug, Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The MCP screen returned 12 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2025-01-14 | Transaction title not available in English source | Phase 3 | Financial terms not disclosed |
| 2023-02-28 | Barts Cancer Institute and Vall d’Hebron Institute collaborate to investigate the effectiveness of savolitinib in combination with durvalumab for treating MET-driven metastatic papillary renal cell carcinoma (mPRC). | Approved | Financial terms not disclosed |
| 2023-01-17 | Erasmus MC and AstraZeneca collaborate to investigate the combined drug effects of durvalumab and rintatolimod in MPDAC patients. | Preclinical | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Anti-b7-h1 and Anti-CTLA-4 antibodies for treating non-small lung cancer”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.
7. Principal risks and diligence gates
- Therapeutic index and off-target toxicity
- Resistance biology and biomarker-defined patient selection
- Differentiation from established and emerging standards
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
CONDITIONAL GO
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 2026-09-16. Counts and status fields may change as source records update.
